BioCentury
ARTICLE | Company News

Valeant Pharmaceuticals, Allergan sales and marketing update

February 14, 2011 8:00 AM UTC

Allergen granted Valeant's Biovail Laboratories International SRL subsidiary exclusive Canadian rights to Aczone dapsone topical gel 5% to treat acne vulgaris. Allergan will receive C$500,000 ($506,050) up front and is eligible for sales-based milestones. The biotech plans to launch the product this year. Further terms were not disclosed. ...